Shenzhen Salubris Pharmaceuticals

About Shenzhen Salubris Pharmaceuticals

Shenzhen Salubris Pharmaceuticals Co., Ltd. is a pharmaceutical group focused on the research, development, manufacturing, and commercialization of medical products. The company's primary therapeutic areas include cardiovascular and cerebrovascular diseases, with a strategic expansion into diabetes, oncology, orthopedics, and infectious diseases. Salubris' business model integrates chemical drugs, biological medicines, and medical devices, aiming to provide comprehensive treatment solutions. Founded in November 1998 by Ye Chenghai, a former vice mayor of Shenzhen, the company initially produced and sold active pharmaceutical ingredients. It transitioned into a drug manufacturer in 2000 and became publicly listed on the Shenzhen Stock Exchange in 2009 (SZSE: 002294). The founder's son, Kevin Ye, who holds an MBA from Yale School of Management, has been the CEO since 2007 and led the company through its public offering. Prior to joining Salubris, Kevin Ye was a business planning manager at HP in California. Salubris has a robust product portfolio and a pipeline of drugs in various stages of development. Its main product areas are cardio-cerebrovascular therapy, diabetes, osteoporosis, and tumors. Key marketed drugs include Taijia (clopidogrel), a generic version of Plavix used to reduce the risk of heart disease and stroke. The company is also developing innovative drugs such as Sacubitril Allisartan Calcium (S086) for hypertension and chronic heart failure, and Enarodustat (SAL0951) for renal anemia. Beyond pharmaceuticals, Salubris develops and markets high-end interventional medical devices for cardiology, cerebrovascular, and structural heart diseases. The company operates a global R&D structure with centers in China and the United States, focusing on small molecule drugs, antibody drugs, gene therapy, and other complex biologics. Its U.S.-based subsidiary, SalubrisBio, is dedicated to developing novel therapeutics for cardiovascular, oncology, and neurodegenerative diseases. Salubris has a global presence, marketing its products in over 30 countries, including the United States, Germany, and Japan.